Price
$6.60+8.02%Social Signal Score
Analyst Ratings
10 analystsRevenue
$31.69MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David T. Hung
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 305
- Beta
- 1.53
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.87
Financials
Revenue
$31.69M+2108.2%Net Income
$-62.84MEBITDA
$-55.55MFree Cash Flow
$-5.02MEPS (diluted)
$-0.18Shares Outstanding (diluted)
348.77M+89.8%Operating Expenses
$73.25MCash & Debt
$660.96MReturn of Capital
$17.14MRevenue by Segment (annual)
$62.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $62.90M | $-204.63M | $-0.60 |
| 2024 | $7.87M | $-567.94M | $-2.11 |
| 2023 | $0.00 | $-75.80M | $-0.35 |
| 2022 | $0.00 | $-104.20M | $-0.48 |
| 2021 | $0.00 | $-86.85M | $-0.44 |
| 2020 | $0.00 | $-41.66M | $-0.19 |
| 2019 | $0.00 | $-33.55M | $-0.16 |
| 2018 | $0.00 | $-992.0K | $-0.01 |
Valuation
NUVBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
85-15.00%Social Signal Score
Mentions (9)
- Newsprnewswire.com·19d ago·Negative
…onger follow-up and no new safety signals identified Approval comes four months ahead of PDUFA date NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic…
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsbenzinga.com·32d ago·Neutral
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec.”
View source ↗ - Newszacks.com·32d ago·Positive
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsprnewswire.com·33d ago·Neutral
Nuvation Bio to Participate in Upcoming Investor Conferences NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D.
View source ↗ - Newszacks.com·35d ago·Positive
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·48d ago·Neutral
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Nuvation Bio Q2 Earnings Call Highlights Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung cancer therapy continued to shift toward first-line patients.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $-0.12 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.15 vs $-0.14miss
- Mon, May 4$0.01 vs $-0.03beat
- Mon, Mar 2$-0.11 vs $-0.11beat
- Mon, Nov 3$-0.16 vs $-0.17beat
- Thu, Aug 7$-0.17 vs $-0.17beat
- Wed, May 7$-0.16 vs $-0.16beat
Estimates and results for NUVB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NUVB officers and directors.
- Bought
- $2.2m
- Sold
- $9.2m
12 trades
17 trades
- Hattersley Garysold
- Markel Stacysold
- Wentworth Kerrysold
- Sauvage Philippesold
- Mashal Robertbought
- Wentworth Kerrysold
- Liu Dongfangsold
- Wentworth Kerrysold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NUVB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.